DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for mucopolysaccharidosis type 4 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMucopolysaccharidosis type 4 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mucopolysaccharidosis type 4 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
galactosidase beta 1 (GLB1) — GLB1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2r,3s,4r,5sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3THD · 1.79 Å · ligand (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol (DGJ). Experimental structure, not a prediction.
What the evidence adds up to
In 1988, a new lymphocyte abnormality called pink rings lymphocyte was described in 9 out of 9 cases of mucopolysaccharidosis type II (Hunter disease) but in only 3 out of 19 cases of other mucopolysaccharidosis types. The sample was 28 children referred to a paediatric department. No treatment or outcome data were reported.
A 2019 case series from Niger reported three children from a consanguineous Touareg family: twin 12-year-old boys and their 10-year-old sister, all diagnosed with Hurler-Scheie syndrome, the intermediate form of mucopolysaccharidosis type I. Diagnosis was confirmed by deficient alpha-L-iduronidase activity in serum and leukocytes. First symptoms appeared at 24 months in the twins and at 3 years in the sister; diagnosis was delayed until age 12 and 10 years respectively. Presenting features included stunted growth, joint stiffness, gait disorders, thoracolumbar spine deformities, recurrent otitis media, hearing loss, increased abdominal volume, snoring, and facial dysmorphism. No treatment or enzyme replacement data were given.
A 2022 case report from Bangladesh, whose full text is not provided, is titled to highlight that limited diagnostic facilities impede therapeutic approaches for mucopolysaccharidosis in that country. No patient numbers, outcomes, or drug names are available from the abstract alone.
A 2018 Russian report on orthopaedic manifestations of mucopolysaccharidosis type I presented 20 patients and noted that orthopaedic signs can be detected from the first months of life, but gave no survival, response rates, or treatment results. The authors stated that low population prevalence leads to delayed diagnosis and inadequate treatment.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PEDIATRICS · 1988 · 9 citations
Pink Rings Lymphocyte: A New Cytologic Abnormality Characteristic of Mucopolysaccharidosis Type II (Hunter Disease)
AbstractTo the Editor.— Mucopolysaccharidoses are a group of rare hereditary storage disorders characterized by various lysosomal hydrolase deficiencies. Clinical condition, radiologic and ophthalmologic examinations, urinary mucopolysaccharides dosage, and leukocyte morphology are generally sufficient for diagnosis.1 However, a more precise classification may be difficult. We herein describe a new lymphocyte abnormality observed in 9/9 cases of type II (Hunter disease) in only 3/19 cases of other types of mucopolysaccharidoses. Capillary blood was collected from 28 children with mucopolysaccharidosis referred to the pediatric department.
Journal of Medical Case Reports · 2019 · 5 citations · open access
Hurler–Scheie syndrome in Niger: a case series
AbstractBACKGROUND: Hurler-Scheie syndrome is an intermediate form of mucopolysaccharidosis type I which is a rare lysosomal storage disorder caused by the deficiency or complete absence of enzyme alpha-L-iduronidase activity. We report the first documented cases of Hurler-Scheie syndrome observed in Niger in a Touareg family. CASE PRESENTATION: We studied the case of two 12-year-old twin Touareg boys and their 10-year-old Touareg sister whose parents are first-degree cousins, and there was no history of similar cases in their previous generations. The diagnosis of Hurler-Scheie syndrome was considered in these patients on the basis of clinical and radiological arguments, with the highlighting of a deficiency of enzyme alpha-L-iduronidase in serum and leukocytes. The twins had presented the first symptoms at the age of 24 months and the diagnosis of Hurler-Scheie syndrome was made at the age of 12 years. In their younger sister, the first symptoms were observed at the age of 3 years and the diagnosis was made at the age of 10 years. The three probands were born after a normal full-term pregnancy and a spontaneous vaginal delivery according to their parents. Their birth weight, height, and head circumference were within normal limits according to their parents. The three probands were brought in for consultation for stunted growth, joint stiffness with gait disorders, deformities of the thoracolumbar spine, recurrent otitis media, decreased hearing, increased abdominal volume, snoring during sleep, and facial dysmorphism. CONCLUSIONS: Even in countries with limited access to diagnostic means, a good knowledge of the clinical manifestations of the disease can help to guide the diagnosis of mucopolysaccharidosis type I.
Sage Journals Data · 2022 · 0 citations · open access
sj-pdf-1-imr-10.1177_03000605221106412 - Supplemental material for Limited diagnostic facilities impeding the therapeutic approach of Mucopolysaccharidosis in Bangladesh: a case report
AbstractSupplemental material, sj-pdf-1-imr-10.1177_03000605221106412 for Limited diagnostic facilities impeding the therapeutic approach of Mucopolysaccharidosis in Bangladesh: a case report by Orindom Shing Pulock, Susmita Dey Pinky and Syeda Humaida Hasan in Journal of International Medical Research
N N Priorov Journal of Traumatology and Orthopedics · 2018 · 0 citations · open access
Clinical manifestations of mucopolysaccharidosis type I (Orthopaedic aspects)
AbstractThe difficulties of differential diagnosis of mucopolysaccharidoses (MPS) type I are conditioned by low population rate of the pathology that results in untimely and inadequate treatment. Case reports for 20 patients with MPS I are presented. Special attention is paid to the orthopaedic manifestations of the pathology that can be determined since the first months of life.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
